<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Treatment of <z:hpo ids='HP_0001635'>heart failure</z:hpo> patients with <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> has been shown to reduce the occurrence of <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Therefore we aimed at determining the consequences of <z:hpo ids='HP_0011010'>chronic</z:hpo> exposure to <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> and the <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> <z:chebi fb="0" ids="31547">eplerenone</z:chebi> and <z:chebi fb="0" ids="9241">spironolactone</z:chebi> on the electrophysiological properties of the heart in a rat model </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: Male Wistar rats were chronically treated (4weeks) with <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALD</z:e>) via an osmotic minipump </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="9241">Spironolactone</z:chebi> (SPI) or <z:chebi fb="0" ids="31547">eplerenone</z:chebi> (EPL) was administered with the rat chow </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALD</z:e> treated animals developed <z:hpo ids='HP_0001712'>left ventricular hypertrophy</z:hpo>, <z:mp ids='MP_0003233'>prolonged QT-intervals</z:mp>, a higher rate of <z:mp ids='MP_0009732'>ventricular premature beats</z:mp> and non-sustained <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> despite <z:mpath ids='MPATH_458'>normal</z:mpath> blood pressure values </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="9241">Spironolactone</z:chebi> and <z:chebi fb="0" ids="31547">eplerenone</z:chebi> were both able to inhibit the alterations </plain></SENT>
<SENT sid="6" pm="."><plain>Left-ventricular <z:chebi fb="2" ids="33699">mRNA</z:chebi> expressions of Kv4.2 and Kv4.3 (Ito), Kv1.5 (IKur), Kir2.1 and Kir2.3 (IK1) and of Cav1.2 (L-type Ca(2+) channel) were significantly down-regulated in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALD</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Correspondingly, the protein expressions of subunits Kv1.5, Kir2.3 and Cav1.2 were significantly decreased </plain></SENT>
<SENT sid="8" pm="."><plain>A diminished calcineurin activity and <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of the AÃŸ subunit of calcineurin were found in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALD</z:e>, which was insensitive to <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi>-overload induces blood pressure independent structural and electrical remodeling of the myocardium resulting in an increased risk for malignant <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
</text></document>